A clinical study on the effects of ?-3 fatty acids on moderate and severe acne and gut microbiota

Not Applicable

Completed

• Conditions: Moderate and severe acne vulgaris; Skin and Connective Tissue Diseases; Acne vulgaris

• Registration Number: ISRCTN31758284
• Lead Sponsor: Affiliated Hospital of Southwest Medical University

Brief Summary

2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38164791/ (added 03/01/2024)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-12-31
• Study Start: 2022-09-07
• Last Update Posted: 15 January 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

1. Patients who meet the criteria for diagnosis and classification of moderate and severe acne vulgaris or healthy volunteers
2. Male or female, at least 18 years of age, maximum age 30 years
3. Body mass index (BMI) 18-25 kg/m²
4. No isotretinoin and ?-3 fatty acids were taken orally within 6 months
5. No drugs were systematically applied within 6 months
6. Participants who have signed the informed consent

Exclusion Criteria

1. Participants with other skin diseases.
2. Participants with immune deficiency or other immune diseases
3. Participants with metabolic diseases such as diabetes and hyperlipidemia
4. Participants with tumors and other serious medical diseases
5. Smokers and alcoholics
6. Pregnant and lactating women
7. Participants who had undergone gastrointestinal surgery
8. Participants with the allergic constitution
9. Participants who known to be allergic to isotretinoin and ?-3 fatty acids
10. Participants who refuse to sign the informed consent form

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
16s rDNA sequence measured from fresh fecal sample at baseline and after 12 weeks of treatment